John I Trujillo - JoVE Visualize

Showing results (11-20 of 24) with videos related to

Pageof 3

Sort By:

Journal of Medicinal Chemistry|November 14, 2018

Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent InhibitorsAgustin Casimiro-Garcia, John I Trujillo, Felix Vajdos, et al.

Journal of Medicinal Chemistry|February 17, 2025

Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 AntagonistsBrian S Gerstenberger, Ray Unwalla, Kathleen A Farley, et al.

Bioorganic & Medicinal Chemistry|April 8, 2020

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.

Journal of Medicinal Chemistry|February 1, 2017

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansAtli Thorarensen, Martin E Dowty, Mary Ellen Banker, et al.

Nature Communications|May 16, 2025

Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding siteLeslie A Dakin, Li Xing, Justin Hall, et al.

ACS Chemical Biology|October 30, 2016

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective InhibitionJean-Baptiste Telliez, Martin E Dowty, Lu Wang, et al.

Nature Communications|August 31, 2024

Structural basis for CCR6 modulation by allosteric antagonistsDavid Jonathan Wasilko, Brian S Gerstenberger, Kathleen A Farley, et al.

ACS Medicinal Chemistry Letters|January 19, 2019

Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group TuningMark E Schnute, Stephen E Benoit, Ingrid P Buchler, et al.

Journal of Medicinal Chemistry|August 17, 2018

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.

ACS Medicinal Chemistry Letters|June 6, 2014

Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)Chris P Carron, John I Trujillo, Kirk L Olson, et al.

Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:

Pageof 3

Journal of Medicinal Chemistry|November 14, 2018

Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent InhibitorsAgustin Casimiro-Garcia, John I Trujillo, Felix Vajdos, et al.

Journal of Medicinal Chemistry|February 17, 2025

Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 AntagonistsBrian S Gerstenberger, Ray Unwalla, Kathleen A Farley, et al.

Bioorganic & Medicinal Chemistry|April 8, 2020

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.

Journal of Medicinal Chemistry|February 1, 2017

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansAtli Thorarensen, Martin E Dowty, Mary Ellen Banker, et al.

Nature Communications|May 16, 2025

Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding siteLeslie A Dakin, Li Xing, Justin Hall, et al.

ACS Chemical Biology|October 30, 2016

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective InhibitionJean-Baptiste Telliez, Martin E Dowty, Lu Wang, et al.

Nature Communications|August 31, 2024

Structural basis for CCR6 modulation by allosteric antagonistsDavid Jonathan Wasilko, Brian S Gerstenberger, Kathleen A Farley, et al.

ACS Medicinal Chemistry Letters|January 19, 2019

Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group TuningMark E Schnute, Stephen E Benoit, Ingrid P Buchler, et al.

Journal of Medicinal Chemistry|August 17, 2018

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.

ACS Medicinal Chemistry Letters|June 6, 2014

Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)Chris P Carron, John I Trujillo, Kirk L Olson, et al.

Pageof 3